Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?

2019-05-22 19:56:22 | BioPortfolio

Published on BioPortfolio: 2019-05-22T19:56:22-0400

Clinical Trials [5075 Associated Clinical Trials listed on BioPortfolio]

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

The ability of glucagon-like peptide 1 to enhance beta-cell responsiveness to I.v. glucose is impaired in patients with type 2 diabetes mellitus compared with healthy individuals. We inves...

GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose

Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, i...

Beta-Cell Function After Near-Normalisation of Blood Glucose

The incretin effect is attenuated in patients with type 2 diabetes mellitus partly due to impaired potentiation of beta-cell responsiveness to glucose by glucose dependent insulinotropic p...

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin releas...

Glucagon Modulation of Ghrelin Secretion

As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulate...

PubMed Articles [10412 Associated PubMed Articles listed on BioPortfolio]

Glucose and Amino Acid Metabolism in Mice Depend Mutually on Glucagon and Insulin Receptor Signaling.

Glucagon and insulin are important regulators of blood glucose. The importance of insulin receptor signaling for alpha cell secretion and of glucagon receptor signaling for beta cell secretion is wide...

Contribution of endogenous glucagon-like Peptide-1 to changes in glucose metabolism and islet function in people with type 2 diabetes four weeks after roux-en-Y gastric bypass (RYGB).

Glucagon-Like Peptide-1 (GLP-1) is an insulin secretagogue which is elevated after Roux-en-Y Gastric Bypass (RYGB). However, its contribution to glucose metabolism after RYGB remains uncertain.

A Novel Measure of Glucose Homeostasis (or Loss thereof) Comprising the Joint Dynamics of Glucose, Insulin, Glucagon and Cortisol.

Quantification of disturbances in glucose-insulin homeostasis has been the cornerstone of appraising insulin resistance and detecting early-stage diabetes. Metabolic homeostasis arises from feedback a...

Optimal regulation of blood glucose level in Type I diabetes using insulin and glucagon.

The Glucose-Insulin-Glucagon nonlinear model accurately describes how the body responds to exogenously supplied insulin and glucagon in patients affected by Type I diabetes. Based on this model, we de...

Glucagon and insulin secretion, insulin clearance and fasting glucose in GIP receptor and GLP-1 receptor knockout mice.

It is not known whether GIP receptor and GLP-1 receptor knockout (KO) mice have perturbations in glucagon secretion or insulin clearance, and studies on impact on fasting glycemia have previously been...

Medical and Biotech [MESH] Definitions

A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.

Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.

Peptide hormones that cause an increase in the absorption of GLUCOSE by cells within organs such as LIVER, MUSCLE and ADIPOSE TISSUE. During normal metabolism insulins are produced by the PANCREATIC BETA CELLS in response to increased GLUCOSE. Natural and chemically-modified forms of insulin are also used in the treatment of GLUCOSE METABOLISM DISORDERS such as DIABETES MELLITUS.

A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).

A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).

More From BioPortfolio on "Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?"

Quick Search


Searches Linking to this Trial